Get started
Author

Julia Catini

Observed names: Catini J, J Catini, J. Catini, Julia N. Catini
OpenAlex ID: A5087195983
The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemia
2016 · James Backes, Deborah Anzalone, et al. · Lipids in Health and Disease · 194
PDF
Changing paradigm in the treatment of amyloidosis: From disease-modifying drugs to anti-fibril therapy
2022 · C. Cristina Quarta, Marianna Fontana, et al. · Frontiers in Cardiovascular Medicine · 25
PDF
1-Year Results from a Phase 2 Study to Determine Safety and Tolerability of Treating Patients with Light-Chain (AL) Amyloidosis with Cael-101, an Anti-Amyloid Monoclonal Antibody, Combined with Anti-Plasma Cell Dyscrasia
2022 · Jason Valent, Michaela Liedtke, et al. · Blood · 8
Safety and Tolerability of Cael-101, an Anti-Amyloid Monoclonal Antibody, Combined with Anti-Plasma Cell Dyscrasia Therapy in Patients with Light-Chain Amyloidosis: 24-Month Results of a Phase 2 Study
2023 · Jason Valent, Michaela Liedtke, et al. · Blood · 5
Safety and Tolerability of Cael-101, an Anti-amyloid Monoclonal Antibody, in Combination With Plasma Cell Dyscrasia Therapy in Patients With Light-chain Amyloidosis: Results From a Phase 2 Study
2022 · Jason Valent, Michaela Liedtke, et al. · Journal of the American College of Cardiology · 5
PDF
Enrolling patients in Cardiac Amyloid Reaching for Extended Survival (CARES) trials: Two placebo-controlled, double-blind, randomized, international phase 3 trials assessing CAEL-101 in patients with Mayo stage IIIa or stage IIIb AL amyloidosis.
2023 · Michaela Liedtke, Giovanni Palladini, et al. · Journal of Clinical Oncology · 4
Diagnostic pathways, cardiac manifestations and outcomes in light chain amyloidosis: analysis of a US claims database
2025 · Genevieve Lyons, Jeffrey Thompson, et al. · Open Heart · 3
PDF
Pb2150: Cardiac Amyloid Reaching for Extended Survival (cares) Trials: 2 Placebo-controlled, Double-blind, Randomized, Phase 3 Trials Assessing Cael-101 in Patients With Mayo Stages Iiia/iiib Al Amyloidosis
2023 · Ashutosh Wechalekar, Giovanni Palladini, et al. · HemaSphere · 3
Evaluation of the Path to Diagnosis and Time to Treatment in Patients with Light-Chain Amyloidosis Using the Komodo Claims Database
2022 · Julia Catini, Quan Doan, et al. · Blood · 3
Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials
2026 · Ashutosh D. Wechalekar, Angela Dispenzieri, et al. · Journal of Clinical Oncology · 2
S204: Safety and Tolerability of Cael-101, an Anti-amyloid Monoclonal Antibody, Combined With Anti-plasma Cell Dyscrasia Therapy in Patients With Light-chain Amyloidosis: 18-month Results of a Phase 2 Study
2023 · Jason Valent, Michaela Liedtke, et al. · HemaSphere · 2
Statins in Chronic Kidney Disease: When and When Not to Use Them.
2016 · Nosratola D Vaziri, Deborah A Anzalone, et al. · PubMed · 2
PDF
Erratum: Efficacy and Safety of Anselamimab in Immunoglobulin Light Chain Amyloidosis: Results From the Randomized CARES Trials
2026 · Ashutosh D. Wechalekar, Angela Dispenzieri, et al. · Journal of Clinical Oncology · 1
EE258 Burden of Systemic Light-Chain (AL) Amyloidosis by Mayo Stage: Results From an Electronic Health Record (EHR) Linked To Claims Analysis
2025 · Jeffrey A. Thompson, Pedro A. Laires, et al. · Value in Health · 1
Treatment Patterns and Outcomes for Patients with Light Chain (AL) Amyloidosis: Analysis of a Large US Claims Database
2023 · Genevieve Lyons, Jeffrey Thompson, et al. · Blood · 1
Safety and tolerability of anselamimab in participants with light chain amyloidosis: Results from a phase 2 study
2026 · Jason Valent, Jeffrey Zonder, et al. · European Journal of Cancer
PA-349 Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light Chain Amyloidosis
2026 · Julia Catini, Ashu Wechalekar, et al. · Clinical Lymphoma Myeloma & Leukemia
Survival of patients newly diagnosed with mayo stage iiia/iiib cardiac light chain amyloidosis on a bortezomib- or daratumumab-based therapy by isotype: results from a single site retrospective study
2026 · J Catini, J Thompson, et al. · European Heart Journal Supplements
POSTER: MM-218: Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis
2026 · Ashutosh Wechalekar, Angela Dispenzieri, et al. · Clinical Lymphoma Myeloma & Leukemia
ORAL ABSTRACT: MM-218: Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis
2026 · Ashutosh Wechalekar, Angela Dispenzieri, et al. · Clinical Lymphoma Myeloma & Leukemia
MM-218: Phase 3 Randomized Trial of Anselamimab Demonstrates Improvement in All-Cause Mortality in κ Light-Chain Amyloidosis
2026 · Ashutosh Wechalekar, Angela Dispenzieri, et al. · Clinical Lymphoma Myeloma & Leukemia
Phase 3 randomized trial to evaluate the impact of anselamimab on all-cause mortality in κ light-chain amyloidosis.
2026 · Ashutosh D. Wechalekar, Angela Dispenzieri, et al. · Journal of Clinical Oncology
Economic Burden of Overall and Advanced Light Chain Amyloidosis: Results from a Claims Linked Electronic Health Record Database Analysis
2026 · Jeffrey Thompson, Ankita Gupta, et al. · ClinicoEconomics and Outcomes Research
Economic Burden of Overall and Advanced Light Chain Amyloidosis: Results from a Claims Linked Electronic Health Record Database Analysis
2026 · Thompson JA, Gupta A, et al. · DOAJ (DOAJ: Directory of Open Access Journals)
Diagnostic pathways, cardiac manifestations, and outcomes in light chain amyloidosis: a plain language summary
2025 · Genevieve Lyons, Jeffrey Thompson, et al. · Future Cardiology
PDF
Works count: 37
Citation count: 259
H-index: 5
I10-index: 2
Year
Topic
Type